 |  |  |  |  |  |  |  |  |  |
Brentuximab vedotin in Hodgkin lymphoma and systemic anaplastic large-cell lymphoma
By: Matt Stenger, MS |
Submitting your vote...
Brentuximab vedotin was recently granted accelerated approval by the Food and Drug Administration for two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplantation (ASCT) or after failure of at least two multiagent chemotherapy regimens in patients who are not candidates for ASCT; and for the treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one multiagent chemotherapy regimen.1 Both indications are based on response rate, with no data currently being available to demonstrate improved outcomes or survival...
* For a PDF of the full article, click in the link to the left of this introduction.
> more Lymphoma & Plasma Cell articles
Community Oncology
Concentrates on original research,
rare cancers, quality of care in
community oncology, and practice guidelines. »
Latest Supplement
Highlights of the 6th Annual Community Oncology Conference. »
For past issues, click here »
| Jun 1 - 5 Chicago, IL | American Society of Clinical Oncology (ASCO): Annual Meeting |
| Jun 14 - 17 Amsterdam, | European Hematology Association (EHA): Annual Congress |
| Jun 18 - 21 Lake Tahoe, NV | American Association for Cancer Research (AACR): Pancreatic Cancer: Progress and Challenges |
| Jun 20 - 22 Milan, | European Institute of Oncology (IEO): 14th Milan Breast Cancer Conference |
| Jun 25 - 26 London, | Teenage Cancer Trust (TCT): International Conference |
| Jun 27 - 30 Barcelona, | European Society for Medical Oncology (ESMO) Conference: World Congress on Gastrointestinal Cancer |
| Jun 27 - 30 Boston, MA | American Association for Cancer Research (AACR): Chemical Systems Biology |
| Jun 28 - 30 New York, NY | Multinational Association of Supportive Care in Cancer (MASCC)/ International Society of Oral Oncology (ISOO): International Symposium |
| Jun 28 - 29 Paris, | WIN 2012 Symposium |
| Jul 7 - 10 Barcelona, | 22nd Biennial Congress of the European Association for Cancer Research |